Minimal impact of selective susceptibility reporting on the use of piperacillin-tazobactam for Escherichia coli and Klebsiella bacteremia

Infect Control Hosp Epidemiol. 2021 Oct;42(10):1272-1274. doi: 10.1017/ice.2020.1385. Epub 2021 Jan 11.

Abstract

Selective cascade reporting of antibiotic susceptibilities did not have a significant impact on de-escalation from piperacillin-tazobactam (PT), duration of PT use, length of stay, or rates of acute kidney injury and Clostridioides difficile infection in patients with positive monomicrobial blood cultures with either Escherichia coli or Klebsiella spp.

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • Bacteremia* / drug therapy
  • Escherichia coli
  • Humans
  • Klebsiella*
  • Piperacillin, Tazobactam Drug Combination

Substances

  • Anti-Bacterial Agents
  • Piperacillin, Tazobactam Drug Combination